BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board


5/13/2008 11:04:19 AM

VANCOUVER, British Columbia and SAN DIEGO, May 13 /PRNewswire/ -- Adnavance Technologies Inc., a developer of direct detection molecular diagnostic tests for medical applications, announced today that it has appointed Christian P. Valcke, Ph.D., to its Scientific Advisory Board. Dr. Valcke has more than 20 years of experience in all aspects of product development, including design, validation, manufacturing and clinical development for medical and diagnostic devices.

Dr. Valcke currently serves as the Senior Director of Instrument Systems at Novartis Vaccines and Diagnostics (NVS), a new division formed as a result of its acquisition of Chiron Corporation. He was previously Vice President of Research and Development at Nanomix, a nanotechnology startup company. Prior to that, Dr. Valcke held several leadership positions at Nanogen, a molecular diagnostics and point-of-care testing company. He has also authored dozens of published research articles and patents.

"Chris is a creative and innovative medical device engineer whom I had the pleasure of working with at Nanogen, and I look forward to working with him again. His contributions, together with Marcelo Baru, our Director of Engineering, will help optimize our direct detection M-DNA platform," said Randy White, Adnavance CEO.

Adnavance Technologies' proprietary ultra-sensitive M-DNA(TM) direct detection technology may eliminate the need for target amplification for a large number of molecular diagnostic tests. Only about 10% of all hospital laboratories and only 35% of all independent laboratories in the U.S. perform molecular diagnostic testing. Adnavance's platform technology has the potential to de-centralize molecular testing and open the market to approximately 30,000 new customers who are currently not licensed to perform medical tests.

"The Company's ultra-sensitive M-DNA technology is new and doesn't rely on light detection, which is an exciting development for a medical device. For the first time, we don't need to consider optical systems for detection, which will significantly lower cost and complexity of the system. I look forward to working with the Adnavance team to bring this exciting technology to market," said Dr. Valcke.

About Adnavance Technologies Inc.

Adnavance is a molecular diagnostic company focused on development of DNA-based tests using the Company's patented metalized DNA (M-DNA) platform. The Company is headquartered in Vancouver, British Columbia and also maintains a DNA development laboratory in San Diego, CA. M-DNA is based on the conducting properties of hybridized DNA. Under strict reaction conditions, certain metal ions can enter the central core of hybridized DNA and displace the hydrogen bonds forming the equivalent of a metal wire in the center of the DNA and making the DNA highly conductive. The Company uses a microarray of 10-micron electrodes to detect the M-DNA and the inherent ultra-sensitivity arises from the differential change in conductivity between hybridized DNA and metalized DNA. This change in conductivity is so large that it obviates the need for target amplification used in current molecular-based tests. Adnavance scientists were the first to discover the M-DNA phenomenon, and the Company believes its technology platform will open new molecular testing markets. For additional information please see the Company website at http://www.adnavance.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate," and similar words indicating uncertainty in facts and figures. Although Adnavance believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove correct. Actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with the technology development process, the risk that Adnavance technology will not gain market acceptance, the risks associated with dependence upon key personnel and the need for additional financing to commercialize the technology platform.

CONTACT: Kim Richards of Porter Novelli Life Sciences, +1-619-849-5377,
krichards@pnlifesciences.com, for Adnavance

Web site: http://www.adnavance.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES